Erratum: Corrigendum to “A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans” (Drug and Alcohol Dependence (2013) 128(3) (222–229) (S0376871612003444) (10.1016/j.drugalcdep.2012.08.027));A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans

Drug and Alcohol Dependence

Volumn 128, Issue 3, 2013, Pages 222-229

  Mitchell, Shannon Gwin ^a   Gryczynski, Jan ^a   Schwartz, Robert P ^a   O'Grady, Kevin E ^b   Olsen, Yngvild K ^c   Jaffe, Jerome H ^a,d  

^a FRIENDS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c Institute for Behavior Resources REACH Health Services   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

African Americans; Buprenorphine; CIDI 2; IOP; Quality of life

Indexed keywords

BUPRENORPHINE;

AFRICAN AMERICAN; AMBULATORY CARE; ARTICLE; COCAINE DEPENDENCE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; FEMALE; HUMAN; MALE; METHODOLOGY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

AFRICAN AMERICANS; AMBULATORY CARE; BALTIMORE; BUPRENORPHINE; COCAINE-RELATED DISORDERS; COUNSELING; FEMALE; HUMANS; MALE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS;

MLCS; MLOWN;

EID: 84880333538     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2016.09.011     Document Type: Erratum

References (22)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th edition - text revised (DSM-IV-TR) 2000, American Psychiatric Publishing, Washington, DC.
2. Bernhard J., Maibach R., Thurlimann B., Sessa C., Aapro M.S. Patients' estimation of overall treatment burden: why not ask the obvious?. J. Clin. Oncol. 2002, 20:65-72.
3. Ducharme L.J., Abraham A.J. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst. Abuse Treat. Prev. Policy 2008, 3:17.
4. Fiellin D.A. The first three years of buprenorphine in the United States: experience to date and future directions. J. Addict. Med. 2007, 1:62-67.
5. Forman R.F., Svikis D., Montoya I.D., Blaine J. Selection of a substance use disorder diagnostic instrument by the National Drug Abuse Treatment Clinical Trials Network. J. Subst. Abuse Treat. 2004, 27(1):1-8.
6. Gottheil E., Weinstein S.P., Sterling R.C., Lundy A., Serota R.D. A randomized controlled study of the effectiveness of intensive outpatient treatment for cocaine dependence. Psychiatr. Serv. 1998, 6:782-787.
7. Gruber V.A., Delucchi K.L., Kielstein A., Batki S.L. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug Alcohol Depend. 2008, 94:199-206.
8. Jaffe J.H., O'Keeffe C. From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend. 2003, 70:S3-S11.
9. Knudsen H.K., Ducharme L.J., Roman P.M. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. J. Subst. Abuse Treat. 2006, 30:363-373.
10. Koch A.L., Arfken C.L., Schuster C.R. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug Alcohol Depend. 2006, 83:274-278.
11. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2008, 2:CD002207.
12. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., Pettinati H., Argeriou M. The fifth edition of the Addiction Severity Index. J. Subst. Abuse Treat. 1992, 9:199-213.
13. McLellan A.T., Hagan T.A., Meyers K., Randall M., Durell J. Intensive" outpatient substance abuse treatment: comparisons with " traditional" outpatient treatment. J. Addict. Disord. 1997, 16:57-84.
14. Metzger D.S., Woody G.E., McLellan A.T., O'Brien C.P., Druley P., Navaline H., DePhilippis D., Stolley P., Abrutyn E. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J. Acquire. Immune Defic. Syndr. 1993, 6:1049-1056.
15. Reisinger H.S., Schwartz R.P., Mitchell S.G., Peterson J.A., Kelly S.M., O'Grady K.E., Marrari E.A., Brown B.S., Agar M.H. Premature discharge from methadone treatment: patient perspectives. J. Psychoactive Drugs 2009, 41:285-296.
16. SAMHSA National Survey of Substance Abuse Treatment Services (N-SSATS) 2007, Office of Applied Studies (OAS), Rockville, MD.
17. Schulz K.F., Altman D.G., Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann. Intern. Med. 2010, 152:726-732. for the CONSORT Group.
18. Schwartz R.P., Kelly S.M., O'Grady K.E., Gandhi D., Jaffe J.H. Interim methadone treatment compared to standard methadone treatment: 4-month findings. J. Subst. Abuse Treat. 2011, 1:21-29.
19. Schwartz R.P., Kelly S.M., O'Grady K.E., Gandhi D., Jaffe J.H. Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings. Addiction 2012, 107:943-952.
20. Weiss R.D., Potter J.S., Fiellin D.A., Byrne M., Connery H.S., Dickinson W., Gardin J., Griffin M.L., Gourevitch M.N., Haller D.L., Hasson A.L., Huang Z., Jacobs P., Kosinski A.S., Lindblad R., McCance-Katz E.F., Provost S.E., Selzer J., Somoza E.C., Sonne S.C., Ling W. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch. Gen. Psychiatry 2011, 68:1238-1246.
21. WESTAT The SAMHSA Evaluation of the Impact of the DATA Waiver Program 2006, Available from:, (retrieved 26.06.12). http://buprenorphine.samhsa.gov/FOR_FINAL_summaryreport_colorized.pdf.
22. World Health Organization The World Health Organization Quality of Life (WHOQOL) - Bref. 2004, WHO, Geneva, Switzerland.